Digital Diagnostics buys 3derm to expand its healthcare AI portfolio
Category: #technology  By Mateen Dalal  Date: 2020-08-21
  • share
  • Twitter
  • Facebook
  • LinkedIn

Digital Diagnostics buys 3derm to expand its healthcare AI portfolio

Digital Diagnostics, a leading global healthcare autonomous AI company previously known as IDx, has reportedly acquired Boston’s 3Derm Systems, making it a worldwide leader in the healthcare autonomous AI field. This also makes the company is the sole holder of De Novo authorized autonomous AI-based healthcare systems. De Novo is an authorization provided by the U.S. FDA (Food & Drug Administration). The authorization allowed the healthcare firm to bridge more gaps that have been broadened due to the coronavirus.

The 3Derm Systems acquisition marks as a crucial milestone towards the effort to utilize autonomous AI to enhance healthcare quality, decrease expenses, as well as lessen the pain caused due to disease progression. The computer takes all medical decisions in “autonomous AI” and not the clinician, allowing patients to receive diagnoses for critical conditions regarding where and when they get medical care. Receiving an instant diagnosis from the frontline care physicians as well as other providers results in better outcomes, particularly for the underserved patients.

Executive Chairman and Founder of Digital Diagnostics, Michael Abramoff, Ph.D., MD stated that patients suffer needlessly from treatable diseases, and the instances of this are more in people that do not get equal access to healthcare facilities, specifically to specialist physicians.

Abramoff further added that the company’s autonomous systems enable frontline care workers to find critical conditions instantly, refer patients that require specialist treatment, and enhance long-term patient results.

The company’s brand name change to Digital Diagnostics from IDx shows its expanded portfolio of autonomous AI products in various medical specialties. Digital Diagnostics’ key product IDx-DR was the first-ever De Novo authorized product by the U.S. FDA within any field of medicine. IDx-DR diagnoses diabetic macular edema and diabetic retinopathy. Through the 3Derm acquisition, the firm would immediately integrate telemedicine capabilities in its platform for dermatology, 3DermTriage,™ to work on FDA authorization for 3DermSpot, the company’s autonomous AI skin cancer diagnostic system.

Source credit: https://dxs.ai/newsroom/digital-diagnostics-formerly-idx-expands-global-impact-of-healthcare-autonomous-ai-with-acquisition-of-3derm-systems-inc/

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

Novartis reveals data from Phase III COMBI-i trial for melanoma
Novartis reveals data from Phase III COMBI-i trial for melanoma
By Mateen Dalal

Swiss-based multinational pharmaceutical company, Novartis has recently revealed detailed results fr...

Curevo declares antibody response data from Phase 1 study of CRV-101
Curevo declares antibody response data from Phase 1 study of CRV-101
By Mateen Dalal

Biopharmaceutical major, Curevo Vaccine, has reportedly announced the release of antibody response d...

CATO SMS announces acquisition of Wilmington-based Array Biostatistics
CATO SMS announces acquisition of Wilmington-based Array Biostatistics
By Mateen Dalal

CATO SMS, one of the leading providers of specialized clinical research solutions, has reportedly ac...